STACKSTONE WEALTH, LLC’s Vertex Pharmaceuticals VRTX Stock Holding History

STACKSTONE WEALTH, LLC’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$2.33M	Buy	+4,465	New	+$2.29M	0.23%	127

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

Montrusco Bolton Investments Montreal, Quebec, Canada $5.77B AUM 24.61% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

Fjarde Ap-fonden Stockholm, Sweden $19.4B AUM 31.69% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return

Czech National Bank Prague, Czech Republic $18.9B AUM 36.24% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 24.77% 1-Year Est. Return

STACKSTONE WEALTH, LLC's VRTX Position: Q3 2026 in Review

STACKSTONE WEALTH, LLC opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 4,465 shares worth $2.33M. The stake represents 0.23% of the portfolio and ranks #127 among its holdings.

346 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

STACKSTONE WEALTH, LLC held 4,465 shares of Vertex Pharmaceuticals worth $2.33M as of Q3 2026.
Vertex Pharmaceuticals was a new STACKSTONE WEALTH, LLC position in Q3 2026.
Vertex Pharmaceuticals made up 0.23% of STACKSTONE WEALTH, LLC's portfolio in Q3 2026, its #127 holding.
346 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on STACKSTONE WEALTH, LLC's 13F filing for Q3 2026, filed 19 Oct 2026.